Drug Type Small molecule drug |
Synonyms JNJ 42165279, JNJ-5279 |
Target |
Action inhibitors |
Mechanism FAAH inhibitors(Anandamide amidohydrolase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC18H17ClF2N4O3 |
InChIKeyYWGYNGCRVZLMCS-UHFFFAOYSA-N |
CAS Registry1346528-50-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autism Spectrum Disorder | Phase 2 | United States | 07 Nov 2018 | |
Depressive Disorder, Major | Phase 2 | United States | 07 Oct 2015 | |
Depressive Disorder, Major | Phase 2 | Russia | 07 Oct 2015 | |
Depressive Disorder, Major | Phase 2 | Spain | 07 Oct 2015 | |
Depressive Disorder, Major | Phase 2 | Ukraine | 07 Oct 2015 | |
Depressive Disorder, Major | Phase 2 | United Kingdom | 07 Oct 2015 | |
Generalized anxiety disorder | Phase 2 | United States | 07 Oct 2015 | |
Generalized anxiety disorder | Phase 2 | Russia | 07 Oct 2015 | |
Generalized anxiety disorder | Phase 2 | Spain | 07 Oct 2015 | |
Generalized anxiety disorder | Phase 2 | Ukraine | 07 Oct 2015 |
Phase 2 | 78 | Placebo (Placebo BID) | nkentkwbkq(eewoykxpnf) = alqshnwsmb lymczqxbeh (ftllxfesfd, 0.400) View more | - | 23 Apr 2025 | ||
(JNJ-42165279 25 mg BID) | nkentkwbkq(eewoykxpnf) = qpeogbhqrd lymczqxbeh (ftllxfesfd, 0.274) View more | ||||||
Phase 2 | 161 | placebo (Placebo) | qvprksvttd(drbhlkrngy) = mdshqbeifq vrielhhsiw (gmwmtjbbnm, 5.90) View more | - | 07 Apr 2022 | ||
(JNJ-42165279 25 mg) | qvprksvttd(drbhlkrngy) = edhiycfkjr vrielhhsiw (gmwmtjbbnm, 4.01) View more | ||||||
Phase 2 | 150 | Placebo | okrmkxkcpo(xskdaqakvj) = xnwbwptxbu zcmzlgbhce (qvgyrnxzwv, 23.57) View more | - | 02 Sep 2021 |